c-Met / HGFR
Los inhibidores de c-Met/HGFR apuntan al Receptor del Factor de Crecimiento de Hepatocitos (c-Met), una tirosina quinasa involucrada en procesos celulares como el crecimiento, la motilidad y la morfogénesis. La señalización de c-Met está implicada en la progresión del cáncer, la metástasis y la resistencia a terapias. Inhibir c-Met puede interrumpir el crecimiento y la propagación del tumor, lo que hace que estos inhibidores sean valiosos en la investigación del cáncer. En CymitQuimica, ofrecemos inhibidores de c-Met/HGFR para apoyar su investigación en oncología, metástasis y terapias contra el cáncer dirigidas.
Productos de "c-Met / HGFR"
Ordenar por
Capmatinib
CAS:Capmatinib (INCB28060) is an orally bioavailable inhibitor of the proto-oncogene c-Met (HGFR)with potential antineoplastic activity.Fórmula:C23H17FN6OPureza:99.24%Forma y color:SolidPeso molecular:412.42Capmatinib 2HCl.H2O
CAS:Capmatinib 2HCl.H2O (NVP-INC280 2HCl.H2O) is an orally bioavailable inhibitor of the proto-oncogene c-Met (HGFR)with potential antineoplastic activity.Fórmula:C23H21Cl2FN6O2Pureza:99.77%Forma y color:SolidPeso molecular:503.36Ref: TM-T8825
2mg35,00€5mg49,00€10mg69,00€25mg115,00€50mg177,00€100mg283,00€200mg378,00€1mL*10mM (DMSO)56,00€Foretinib
CAS:Foretinib (GSK1363089) is a broad-spectrum tyrosine kinase inhibitor with IC50s of 0.4 nM and 0.9 nM for Met and KDR.Fórmula:C34H34F2N4O6Pureza:98.07% - 99.68%Forma y color:SolidPeso molecular:632.65Ref: TM-T3113
2mg39,00€5mg57,00€10mg79,00€25mg133,00€50mg207,00€100mg354,00€500mg848,00€1mL*10mM (DMSO)79,00€Antitumor agent-111
Antitumor Agent-111 (Compound 46), a c-Met kinase inhibitor (IC50 = 46 nM), exhibits both antitumor and antiproliferative effects.Fórmula:C34H29ClF2N6O5Pureza:98%Forma y color:SolidPeso molecular:675.08Pamufetinib
CAS:Pamufetinib (TAS-115) is a potent inhibitor of VEGFR and hepatocyte growth factor receptor (c-Met/HGFR)-targeted kinase.Fórmula:C27H23FN4O4SPureza:99.39%Forma y color:SolidPeso molecular:518.56Ref: TM-T13108
1mg50,00€5mg106,00€10mg158,00€25mg258,00€50mg379,00€100mg538,00€200mg733,00€1mL*10mM (DMSO)134,00€JNJ-38877618
CAS:JNJ-38877618 (OMO-1) is an effective and highly selective inhibitor of Met kinase (IC50s: 2 and 3 nM for wild type and mutant Met, respectively).Fórmula:C20H12F2N6Pureza:98.84% - 99.52%Forma y color:SolidPeso molecular:374.35Ref: TM-T15617
1mg63,00€2mg89,00€5mg137,00€10mg210,00€25mg424,00€50mg627,00€100mg893,00€500mg1.786,00€1mL*10mM (DMSO)153,00€Rilotumumab
CAS:Rilotumumab (AMG 102) is an HGF-targeting antibody, inhibits HGF/MET signaling, and is used for CRPC and gastric cancer research.Pureza:SDS-PAGE:95% SEC-HPLC:97.51%Forma y color:LiquidPeso molecular:145.2 kDaAltiratinib
CAS:Altiratinib (DCC-2701)(DCC-2701) is a novel c-MET/TIE-2/VEGFR inhibitor; effectively reduce tumor burden in vivo and block c-MET pTyr(1349)-mediated signaling,Fórmula:C26H21F3N4O4Pureza:98.98% - 99.39%Forma y color:SolidPeso molecular:510.46BAY-474
CAS:BAY-474 is an inhibitor of tyrosine-protein kinase c-Met. It acts as an epigenetics probeFórmula:C17H15N5Pureza:98.98%Forma y color:SolidPeso molecular:289.33Ref: TM-T7900
1mg50,00€5mg97,00€10mg170,00€25mg306,00€50mg444,00€100mg620,00€200mg835,00€1mL*10mM (DMSO)114,00€Capmatinib xHCl
CAS:Capmatinib xHCl (INCB28060) is a potent, orally active, selective, and ATP competitive c-Met kinase inhibitor, potently blocking in vitro kinase activity (IC50Fórmula:C23H18ClFN6OPureza:98.62% - 99.12%Forma y color:SolidPeso molecular:448.89Telisotuzumab
CAS:Telisotuzumab(ABT-700) is a humanized recombinant antibody targeting the therapeutic hepatocyte growth factor receptor (MET) with high affinity for c-Met.Pureza:SDS-PAGE:96.4%;SEC-HPLC:98.5%Forma y color:LiquidPeso molecular:145.50 kDaTerevalefim
CAS:Terevalefim (ANG-3777) is an hepatocyte growth factor (HGF) mimetic. Terevalefim selectively activates the c-Met receptor.Fórmula:C9H8N2SPureza:99.53%Forma y color:SolidPeso molecular:176.24Ref: TM-T37596
1mg56,00€5mg119,00€10mg210,00€25mg369,00€50mg537,00€100mg750,00€500mg1.539,00€1mL*10mM (DMSO)119,00€BMS 777607
CAS:BMS 777607 (BMS 817378) is a Met-related inhibitor for c-Met/Axl/Ron/Tyro3. BMS-777607 has been investigated for the basic science of Malignant Solid Tumour.Fórmula:C25H19ClF2N4O4Pureza:100% - 99.89%Forma y color:SolidPeso molecular:512.89Ref: TM-T2699
1mg35,00€5mg79,00€10mg124,00€25mg217,00€50mg359,00€100mg533,00€500mg1.169,00€1mL*10mM (DMSO)92,00€Tyrosine kinase inhibitor
CAS:Tyrosine kinase inhibitor is a tyrosine kinase inhibitor used in combination with fragmenting aromatic nitrogen compounds as antiproliferative agents.Fórmula:C31H31FN6O5Pureza:98%Forma y color:SolidPeso molecular:586.61CSF1R-IN-2
CAS:CSF1R-IN-2 is an oral-active SRC, MET and c-FMS inhibitor (IC50s: 0.12 nM, 0.14 nM and 0.76 nM for SRC, MET and c-FMS respectively).Fórmula:C20H20FN7O2Pureza:99.29%Forma y color:SolidPeso molecular:409.42C-Met inhibitor D9
CAS:C-Met inhibitor D9 is a c-Met kinase inhibitor.Fórmula:C17H15N3O2Pureza:97%Forma y color:SolidPeso molecular:293.32BMS-794833
CAS:BMS-794833 is a potent ATP competitive inhibitor of Met/VEGFR2; a prodrug of BMS-817378.Fórmula:C23H15ClF2N4O3Pureza:98% - 99.69%Forma y color:SolidPeso molecular:468.84Ref: TM-T2419
1mg42,00€2mg52,00€5mg88,00€10mg150,00€25mg296,00€50mg537,00€100mg772,00€1mL*10mM (DMSO)95,00€LMTK3-IN-1
CAS:Lmtk3-in-1 is a potent ATP-competitive lemur tyrosine kinase 3 (LMTK3) (Kd=2.5 μM) inhibitor that degrades LMTK3 through the ubiquitin proteasome pathway.Fórmula:C18H11F3N4OPureza:100%Forma y color:SoildPeso molecular:356.3SCR-1481B1
CAS:SCR-1481B1 (c-Met inhibitor 2) has activity against cancers dependent on Met activation and also has activity against cancers as a VEGFR inhibitorFórmula:C32H40ClF2N6O13PPureza:98.07%Forma y color:SolidPeso molecular:821.12Ref: TM-T5349
1mg38,00€2mg49,00€5mg79,00€10mg119,00€25mg210,00€50mg350,00€100mg522,00€1mL*10mM (DMSO)107,00€XL092
CAS:XL092 (JUN04542) is an Axl Mer cMet KDR inhibitor for the treatment of Axl and Mer receptor tyrosine kinase- dependent disorders.Fórmula:C29H25FN4O5Pureza:98.60%Forma y color:SolidPeso molecular:528.53Ensartinib hydrochloride
CAS:Ensartinib hydrochloride (X-396 dihydrochloride) is a potent new-generation ALK inhibitor with high activity against CNS metastases and a broad range of knownFórmula:C26H29Cl4FN6O3Pureza:98.73%Forma y color:SolidPeso molecular:634.36Ref: TM-T22324
1mg66,00€2mg93,00€5mg144,00€10mg227,00€25mg464,00€50mg677,00€100mg938,00€1mL*10mM (DMSO)188,00€JNJ-38877605
CAS:JNJ-38877605 is an ATP-competitive c-Met inhibitor (IC50: 4 nM), 600-fold selective for c-Met than 200 other tyrosine and serine-threonine kinases.Fórmula:C19H13F2N7Pureza:97.04% - 98.27%Forma y color:SolidPeso molecular:377.35EGFR-IN-8
CAS:EGFR-IN-8, a dual inhibitor targeting both EGFR and c-Met, shows potential as a promising candidate for further development in treating EGFR TKI-resistant NSCLCFórmula:C32H23ClF3N7O4Pureza:97.45%Forma y color:SolidPeso molecular:662.02Glesatinib hydrochloride
CAS:Glesatinib hydrochloride is an orally active and potent dual inhibitor of MET/SMO.Fórmula:C31H28ClF2N5O3S2Pureza:98%Forma y color:SolidPeso molecular:656.16NPS-1034
CAS:NPS-1034 is a dual Met/Axl inhibitor with IC50 of 48 nM and 10.3 nM, respectively.Fórmula:C31H23F2N5O3Pureza:98.48%Forma y color:SolidPeso molecular:551.54Ningetinib Tosylate
CAS:Ningetinib Tosylate is an orally bioavailable tyrosine kinase inhibitor with IC50s of <1.0, 1.9 and 6.7 nM for Axl, VEGFR2, and c-Met, respectively.Fórmula:C38H37FN4O8SPureza:99.93%Forma y color:SolidPeso molecular:728.79PF-04217903 phenolsulfonate
CAS:PF-04217903 phenolsulfonate is a potent ATP-competitive inhibitor of c-Met kinase (Ki of 4.8 nM for human c-Met).Fórmula:C25H22N8O5SPureza:98%Forma y color:SolidPeso molecular:546.56Savolitinib
CAS:Savolitinib (Volitinib) (AZD-6094) is an effective, selective, and orally bioavailable c-Met inhibitor (IC50s: 5 nM/3 nM for c-Met/p-Met).Fórmula:C17H15N9Pureza:98.12%Forma y color:SolidPeso molecular:345.36Ref: TM-TQ0210
1mg49,00€2mg64,00€5mg92,00€10mg131,00€25mg210,00€50mg373,00€100mg567,00€1mL*10mM (DMSO)97,00€SAR125844
CAS:SAR125844, a potent and highly selective inhibitor of the MET receptor tyrosine kinase (RTK), for intravenous administration. (IC50 value of 4.2 nmol/L)Fórmula:C25H23FN8O2S2Pureza:98.39%Forma y color:SolidPeso molecular:550.63Ref: TM-T5467
1mg35,00€5mg79,00€10mg116,00€25mg227,00€50mg364,00€100mg588,00€200mg833,00€1mL*10mM (DMSO)96,00€Afatinib Dimaleate
CAS:Afatinib Dimaleate (BIBW 2992MA2) is an orally bioavailable anilino-quinazoline derivative and inhibitor of the EGFR family, with antineoplastic activity.Fórmula:C32H33ClFN5O11Pureza:100% - 98.11%Forma y color:SolidPeso molecular:718.08Ref: TM-T1773
1g467,00€5mg40,00€10mg59,00€25mg87,00€50mg107,00€100mg140,00€200mg188,00€500mg313,00€1mL*10mM (DMSO)66,00€Fosgonimeton acetate
Fosgonimeton acetate is an agonist of hepatocyte growth factor (HGF).Fórmula:C29H49N4O10PPureza:97.05%Forma y color:SolidPeso molecular:644.69Ref: TM-T39507L
1mg116,00€2mg160,00€5mg238,00€10mg353,00€25mg563,00€50mg758,00€100mg1.017,00€200mg1.359,00€Bozitinib
CAS:Bozitinib (PLB-1001) (PLB-1001) is a highly selective inhibitor of the c-MET kinase with blood-brain barrier permeability.Fórmula:C20H15F3N8Pureza:99.16%Forma y color:SolidPeso molecular:424.38Ref: TM-T10585
1mg97,00€5mg216,00€10mg354,00€25mg628,00€50mg905,00€100mg1.264,00€200mg1.700,00€1mL*10mM (DMSO)240,00€c-Met-IN-2
CAS:c-Met-IN-2 is a selective and orally available c-Met inhibitor (IC50: 0.6 nM) with antitumor activity.Fórmula:C24H21FN10OPureza:98%Forma y color:SolidPeso molecular:484.49PROTAC c-Met degrader-3
PROTACc-Met degrader-3 (Compound 22b) is a c-Met PROTAC degrader. It facilitates the ubiquitination and degradation of c-Met, with a DC50 of 0.59 nM in EBC-1 cells. PROTACc-Met degrader-3 is applicable in lung cancer research.Fórmula:C51H54N10O7Forma y color:SolidPeso molecular:919.037(Z)-Semaxinib
CAS:(Z)-Semaxinib (SU5416) is a potent and selective VEGFR(Flk-1/KDR) inhibitor (IC50: 1.23 μM), 20-fold more selective for VEGFR over PDGFRβ, no inhibition forFórmula:C15H14N2OPureza:96.09% - ≥95%Forma y color:SolidPeso molecular:238.28Ref: TM-T2496
1mg57,00€5mg111,00€10mg188,00€25mg331,00€50mg568,00€100mg695,00€200mg948,00€1mL*10mM (DMSO)144,00€MK-2461
CAS:MK-2461 is a novel inhibitor that targets multiple proteins and competitively binds to ATP sites, specifically inhibiting the activated c-Met protein with anFórmula:C24H25N5O5SPureza:95.41% - 99.53%Forma y color:SolidPeso molecular:495.55Ref: TM-T6094
1mg52,00€5mg120,00€10mg187,00€25mg363,00€50mg552,00€100mg842,00€200mg1.130,00€1mL*10mM (DMSO)134,00€NVP-BVU972
CAS:NVP-BVU972 is a selective and potent Met inhibitor with IC50 of 14 nM.Fórmula:C20H16N6Pureza:100% - 98.61%Forma y color:SolidPeso molecular:340.38Ref: TM-T2680
2mg44,00€5mg74,00€10mg97,00€25mg178,00€50mg255,00€100mg359,00€200mg510,00€1mL*10mM (DMSO)84,00€AMG-337
CAS:AMG-337 is an effective and highly specific ATP-competitive MET kinase inhibitor. In enzymatic assays, AMG-337 inhibits MET kinase activity (IC50: < 5 nM).Fórmula:C23H22FN7O3Pureza:99.26% - 99.9%Forma y color:SolidPeso molecular:463.46Ref: TM-T3209
1mg40,00€2mg52,00€5mg85,00€10mg124,00€25mg197,00€50mg350,00€100mg522,00€200mg748,00€1mL*10mM (DMSO)86,00€MET/PDGFRA-IN-2
MET/PDGFRA-IN-2 (compound 8h) serves as an inhibitor of MET and PDGFRA proteins, promoting apoptosis in cells and impeding the proliferation of MET-positiveFórmula:C29H29N7OPureza:98%Forma y color:SolidPeso molecular:491.59c-Met-IN-17
c-Met-IN-17 is a potent inhibitor of c-Met kinase, demonstrating an IC50 of 0.031 μM, and is applicable in anticancer research. [1]Fórmula:C21H15FN4O2Pureza:98%Forma y color:SolidPeso molecular:374.37
